



Emerging Risk: Cancer Products and Associated Risks

Zhee Koh, FSA, Head of L&H Pricing (India) 4th IAI Seminar on ERM 3 December 2015



People hear the word cancer and they immediately think death sentence. I was told to keep quiet about my illness - Lisa Ray


By the end of it, I would have run away if a fourth cycle (of chemo) was necessary, even if it meant I'd die... I didn't want to enter the hospital again -Yuvraj Singh

The worst pain I suffered was because of the injections given to increase the white blood cell count. I remember telling my mother, 'If this is the pain I have to go through I rather die.' - Manisha Koirala



The "good" news...


- India is estimated to have around 1 million new cases per year, with incidence rate around 94 per 100,000 (weighted mean of the age-specific rates)
- Lower than most emerging and developed markets across the globe



Sources: Globocan 2012, EY analysis

The not-so-good news...

• India has a poor detection rate with only 20-30% of cancers being diagnosed in stages I and II, which is less than half of that in China, the UK and the US



Sources: (1) EY Call for Action: Expanding cancer care in India, July 2015



The not-so-good news...


AAU TTAUC FACTED

- Mortality rates (due to cancer) are four to six times higher in India than other developed nations (e.g. US)
- Less than 1/3 of patients are alive more than 5 years after their diagnosis, and
- Three quarters of cancer deaths occur during their prime productive years

i cancer pa	tients who survive	s years alle	ulayilosis
\frown		INDIA	Most countries
	Liver	4	10-20
) Leukemia*	6	50-60
	Lung	10	10-20
	Ovary	14	30-40
	Stomach	19	25-30
2	Rectum	29	50-59

The not-so-good news...

• World's highest rates of cervical, gall bladder, oral, pharynx cancers are in India



Sources: http://indiatoday.intoday.in/story/cancer-disease-india-chemotherapy-manisha-koirala/1/340991.html



The bad news...



Sources: Global Burden of Cancer Studies, GLOBOCAN, WHO, 2012



The bad news... Cancer Treatment Cost Scenario

- Female, age 45 years, diagnosed with breast cancer
- Initial Lumpectomy was done. Surgery Cost INR 1.25 lac
- HER positive will respond to "wonder drug" HERCEPTIN (very high success rate/less side effects compared to normal chemo
- HERCEPTION costs INR 75,000 per vial of 440 mgs
 - Need may be 15-20 doses over a period of 1-2 yrs= INR 11-15 lacs
- This is given with conventional chemo- costing around INR 1.5 to 2 lac
- Radiation may be required in some cases : range from INR 1.5-3 lac
- Total cost of the **first battle** with cancer was approximately INR 15-20 lac



Swiss drugmaker Roche launches costliest cancer drugs in India

By DIVYA RAJAGOPAL, ET Bureau | 26 Nov, 2015, 06.34AM IST

Post a Comment

READ MORE ON » Roche | Perjeta | Kadcyla | Cancer | Biocon

MUMBAI: As insurers, patients and governments across the world debate over the rising cost of healthcare, Swiss pharmaceutical major Roche has boldly launched two new drugs for late-stage breast cancer, pricing them higher than any other cancer medicine in the Indian market.

Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET verified the price with several chemists and doctors, who said the maximum discount that was available was in the range of Rs 10,000-

ET SPECIAL: Love visual aspect of news? Enjoy this exclusive slideshows treat!

15,000. Roche said it gives the drugs free of cost after an initial stage of treatment.

These drugs are given when the cancer becomes metastatic, or in simple terms when the tumour spreads to other parts of the body where the chances of cure are negligible. They are recommended when patients fail to respond to Herceptin (trastuzumab), the most commonly prescribed treatment for breast cancer.

The cost of the drugs over a nine-month period hovers around Rs 12 lakh for Kadcyla and Rs 30 lakh for Perjeta. In India, Roche collaborated with Pune-based Emcure Pharmaceuticals to sell Herceptin under a local brand name, Herclon, which costs about Rs 65,000 a vial.

Critical Illness evolution across different Asian markets

Single Impairment Cover

Standard 10 - 30 Major Cl


Comprehensive Cover

- Cancer only products
- Japan / Korea popular for different reasons
- Typical Benefits:
 - Diagnosis lump sum
 - Hospital cash
 - Surgical cash
- Segment specific Senior
- Treatment based benefits

- Race on features / number
- China / HK / SEA some standardisation
- Reinstatement Options / Cover Buy Back
- Multiple Pay Cl
- Severity based cover Early Stage CI
- Multiple Pay Severity based CI (Pot CI)

Cancer Relapse Cover

Cancer relapse benefit pays a additional benefits as long as there are residual cancer cells within the body every 2 years.



The cancer re-diagnosed benefit pays 50% S.A. as long as there are residual cancer cells for all major cancer within the body every 2 years, maximum 2 payouts per life (including the first diagnosis):


- ✓ First primary cancer persists to more than 2 years since first diagnosis
- ✓ Metastasis cancer of the first cancer organ to other parts of the body
- ✓ Though recovered temporarily, the same cancer recurred at the same organ as the first cancer

New primary cancer unrelated to the first


Only this item covered in current market's multiple pay cover



AXA SG - Cancer 360



What about Cancer <u>Reimbursement</u> version?



Can Actuaries Foresee the Future?





Retrospective projection


- Derive a trend mainly from the numeric incidence rates in the past; and
- Apply this trend for the future for a period of time with/without a cap.

Pros and Cons	
Simple & easy to explain	
Better than nothing?	
Requires credible, relevant data	
Projection period/ultimate cap are subjective	
Relevance of past to future?	
Sensitive to data period used	



Trend Approaches


Past data can give a very different answer, depending on the period considered



Hong Kong cancer registry online query system

Drilling deeper


• Before making assumptions for the future, it is necessary to understand the circumstances that drove current and past experience




Spike in ASR is driven by specific ages and coincides with the key screening age group

Retrospective method does not allow for this


Breast cancer



- How to project forward breast cancer incidence rates in Shanghai?
 - extrapolation?
 - external benchmarks? which one?



Fertility rate & breast cancer



- Link between breast cancer risk and hormone status during reproductive ages
 - Did we have a 20-30 year advance notice?

Fertility rate & breast cancer




FIGURE 4 – IRRs of breast cancer diagnosed 1968–1997 by birth cohort, with the 1928 birth cohort as reference group. Estimates derived from age-cohort models fitted to younger (< 45) and older (\geq 45) women. Dotted lines, premenopausal women; solid lines, postmenopausal women.

FIGURE 5 – Total fertility rates (age 15–44) for Sweden and Singapore from 1964 to 1997. Source: Registrar-General of Births and Deaths, Republic of Singapore (1978–1997). Total Population Register, Statistics Sweden (1964–1997).

Similar patterns observed in other countries

🖬 Swiss Re

What else do we know?

To estimate future cancer incidence, it is necessary to estimate the changes in the underlying causal factors

- Breast cancer (c30%)
 - Obesity, alcohol intake, hormones, occupation, diet, ...
- Lung Cancer (c90%)
 - Smoking, Occupational hazards, Low fruit & veg, Radiation, ...
- Stomach cancer (c80%)
 - Low fruit & veg, infection, salt intake, tobacco, ...
- Bowel cancer (c60%)
 - Red meat, obesity, low fibre, alcohol, tobacco, infection, inactivity, ...
- Malignant melanoma (>90%)
 - sunlight/sunbeds, ...

Source: cancer research, UK

Prospective projection

- Emphasis of understanding of risk factors, with focus on key and modifiable ones
- Evaluate the relative importance (e.g. attributable fraction) of risk factors
- Project the change of these risk factors and measure the impact on cancer incidence rate

Pros and Cons	
Less reliance on past experience data	\checkmark
Allows for known changes	\checkmark
Theoretically more sound	\checkmark
More complex	×
Intensive research required	
Not all risk factors have been identified	




Case Study: Liver Cancer



Current liver cancer trends in Asia

• Incidence has generally reduced over last 30 years



- Why a reduction, and will it continue? How long?
- Why is Japanese shape so different?

Swiss Re

Risk factors

	Risk (95% Cl)
Hepatitis B	- Pooled RR: 11.6 (8.3-16.3)
Virus (HBV)	- Higher in HBV genotype C
Hepatitis C	- Pooled RR: 7.4 (4.3-12.8)
Virus (HCV)	- Higher in HCV genotype 1b
Aflatoxin B1	- Pooled OR: 6.4 (3.7-10.9)
Anatoxin B I	- Higher in HCV genotype 1b




Hepatitis prevalence has been reducing

	HBV prevalence rate	Change	Notes	
CN	9.8% in 1992, 7.2% in 2006	-27%	National serosurvey of HBV, age 1–59	
НК	11.3% in 1990, 7.4% in 2011	-35%	Hepatitis surveillance, antenatal women	
TW	14.3% in 1995, 1.1% in 2009	-92 %	University freshmen	
JP	1.1%	n/a	National health screening for HbsAg, age 40+	
KR	4.5% in 1998, 3.7% in 2005	-18% National health & nutrition survey in Korea, 10+		
SG	4.0% in 1999, 2.8% in 2005	-30%	-30% National health survey, age 18–69	

Results of intervention


- Aflatoxin has improved in the past and now generally under control.
- Transmission of HBV/HCV via blood products well reduced in most countries
- Treatment becoming more effective:
 - Control of HBV (although not a cure) can reduce liver cancer risk by 40-50%.
- Success in treatment for HCV may compensate for lack of vaccination,
- Vaccination for HBV well established in many countries over last 10-30 years
 - Reduction in prevalence will be observed as vaccinated population ages



Source: Epidemiological sero-survey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination A quantitative approach (China, 40 – 49)




A quantitative approach (China, 40 - 49)



Case Study: Thyroid Cancer



An increasing risk




According to a 2014 report:

- In 2012, it increased by about 40% compared to 2011 - ranked No. 4. female cancer
- Similar findings also observable in Shenzhen, Shanghai etc.
- Some insurance companies have reported alarming trend of thyroid cancer claims, especially in eastern provinces/cities.

It is not a potential risk anymore but a realistic one.


Similar pattern in Korea

Trends of Age-standardized Incidence Rates of Major Cancers : Female



Source) Ministry of Health & Welfare, Korea Central Cancer Registry, 2012 Note) ASR (Age-standardized rate) standard population: Korean mid-year population in 2010

Projection for Beijing




Incidence is sensitive to assumed detection rate, but shows how rapidly rates could increase should screening prevalence increase



How high can it go?

- "Natural" incidence
 - up to 0.01%
- Screening detection rate
 - 0.3%-2.6% (varies by study)
 - c100x natural rate
- Autopsy prevalence rate
 - 10-20% in Asian countries
 - Claims rate could increase as diagnostic methods





Risk Management Tools

- Mandatory exclusion as part of policy conditions ex-survival period, waiting period etc.
- Limiting maximum payout or excluding lower severity cancers
- Tight policy wording on definitions of cancers and medically necessary treatments (for reimbursement feature)
- Periodic experience monitoring good quality data is key!
 - Early warning signals to detect issues in advance
 - Ability to react quickly and effectively
- Scenario testing



Key Takeaways

- Cancer plans evolution needs to consider the following:
 - Adequate coverage to consumers
 - Simple to understand for agents/consumers
 - Operational infrastructure to support (claims/uw, VAS, etc.)
- To estimate future cancer incidences, given the interaction of numerous moving parts, extrapolating past experience is insufficient
- Considering underlying drivers can help, but
 - each cancer has numerous risk factors, that are not fully understood
 - detailed analysis is informative, but risk remains
- Long term guarantees mean future incidence rates require significant thought



Thank you

Legal notice

[©]2015 Swiss Re. All rights reserved. You are not permitted to create any modifications or derivative works of this presentation or to use it for commercial or other public purposes without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and are subject to change without notice. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for the accuracy or comprehensiveness of the details given. All liability for the accuracy and completeness thereof or for any damage or loss resulting from the use of the information contained in this presentation is expressly excluded. Under no circumstances shall Swiss Re or its Group companies be liable for any financial or consequential loss relating to this presentation.

